Trial Profile
Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (NEUPRODEX)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Delirium
- Focus Therapeutic Use
- Acronyms Neuprodex
- 07 May 2021 Primary endpoint has been met. (Incidence of postoperative delirium measured with the Confusion Assessment Method for the ICU (CAM-ICU) or the Confusion Assessment Method (CAM) and/or Chart Review and/or DSM V/ICD-10), as per Results published in the Anaesthesia
- 07 May 2021 Results published in the Anaesthesia
- 20 Aug 2018 Status changed from recruiting to completed.